Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

By LabMedica International staff writers
Posted on 16 Nov 2026

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories. More...

Expanding access to decentralized testing requires technologies that balance speed, simplicity, and diagnostic performance. A new molecular diagnostics platform demonstrates sample-to-answer detection in under 10 minutes using CRISPR technology without target amplification.

VedaBio presented proof-of-concept data for its integrated, target amplification-free CRISPR-based molecular diagnostics platform at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo in Seattle, Washington. The technology is being developed to address five key priorities in molecular testing: speed, simplicity, breadth, accuracy, and cost-effectiveness. The findings were presented in a technical poster titled “Target-Amplification-Free CRISPR-Cas Nucleic Acid Detection with OR-Logic Multiplexing Enables Clinically Relevant, Rapid Point-of-Care Testing.”

The integrated prototype was evaluated in a proof-of-concept study using a five-result respiratory panel, demonstrating rapid multiplex molecular detection through a workflow that included automated nucleic acid extraction. Unlike conventional molecular methods, the CRISPR-based technology detects targets without requiring amplification, potentially reducing testing time and procedural complexity.

The demonstration achieved sample-to-answer results in under 10 minutes, highlighting the platform’s potential to combine rapid multiplex detection with a streamlined workflow. VedaBio is developing the technology for decentralized and point-of-need testing, including urgent care and other settings where timely molecular diagnostics could support clinical decision-making.

“Molecular diagnostics should not have to come with trade-offs between speed, complexity and performance. Our goal is to challenge those limitations and bring the benefits of molecular testing closer to patients. These findings demonstrate exciting progress toward that vision and underscore the potential of our CRISPR-based approach to help redefine what is possible at the point of care,” said Brett Robb, PhD, Chief Scientific Officer of VedaBio.

Related Links
VedaBio


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.